share_log

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

艾伯维公司 | S-8：员工福利计划证券登记
美股SEC公告 ·  08/14 16:11
Moomoo AI 已提取核心信息
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has successfully completed the acquisition of Cerevel Therapeutics Holdings, Inc. on August 1, 2024, as per the Merger Agreement dated December 6, 2023. Following the merger, AbbVie has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission to register shares of common stock that may be issued under the Cerevel 2020 Equity Incentive Plan. This plan has been assumed by AbbVie, and certain restricted stock unit awards previously granted under the plan have been converted into awards for AbbVie common stock. These converted awards will continue to be governed by the terms of the Cerevel Plan post-merger. The registration of these shares enables the settlement of the converted awards for AbbVie employees who held equity in Cerevel.
美国生物制药公司艾伯维公司于2024年8月1日依照于2023年12月6日签订的合并协议成功收购了Cerevel Therapeutics Holdings公司。合并后，艾伯维已向美国证券交易委员会提交了S-8表格的注册声明，以登记在Cerevel 2020年权益激励计划下发行的普通股。该计划已被艾伯维承担，该计划之前授予的某些限制性股票单位奖励已转换为艾伯维普通股奖励。这些转换的奖励将在合并后继续按Cerevel计划的条款管理。这些股票的注册使持有Cerevel股权的艾伯维员工能够结算转换后的艾伯维奖励。
美国生物制药公司艾伯维公司于2024年8月1日依照于2023年12月6日签订的合并协议成功收购了Cerevel Therapeutics Holdings公司。合并后，艾伯维已向美国证券交易委员会提交了S-8表格的注册声明，以登记在Cerevel 2020年权益激励计划下发行的普通股。该计划已被艾伯维承担，该计划之前授予的某些限制性股票单位奖励已转换为艾伯维普通股奖励。这些转换的奖励将在合并后继续按Cerevel计划的条款管理。这些股票的注册使持有Cerevel股权的艾伯维员工能够结算转换后的艾伯维奖励。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息